Inhibition of BET proteins leads to an increase in BIM, which may cooperate with BIM induction following MAPK inhibition and early data suggest that combining BET inhibitors and MAPK inhibition may be advantageous in melanoma [52,55,100]. The gene discussed is BCL2L11; the disease is melanoma.